Relapses in the Guillain-Barre syndrome after treatment with intravenous immune globulin or plasma exchange

Muscle and Nerve

Volumn 21, Issue 10, 1998, Pages 1327-1330

  Romano, J G ^a   Rotta, F T ^a   Potter, P ^a   Rosenfeld, V ^a   Santibanez, R ^a   Rocha, B ^a   Bradley, W G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Guillain Barre syndrome; Intravenous immune globulin; Plasma exchange; Relapses

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ARTICLE; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE;

ADULT; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MEDICAL RECORDS; PLASMA EXCHANGE; POLYRADICULONEUROPATHY; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 0031723490     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199810)21:10<1327::AID-MUS14>3.0.CO;2-Z     Document Type: Article

References (16)

1. Asbury AK, Arnason BG, Adams RD: Criteria for diagnosis of Guillain-Barre syndrome. Ann Neurol 1978;3:565-566.
2. Castro LHM, Ropper AH: Human immune globulin infusion in Guillain-Barre syndrome: worsening during and after treatment. Neurology 1993;43:1034-1036.
3. Dutch Guillain-Barre Study Group: Treatment of Guillain-Barre syndrome with high dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994;35:749-752.
4. Guillain-Barre Syndrome Study Group: Plasmapheresis and acute Guillain-Barre syndrome. Neurology 1985;35:1096-1104.
5. Hughes RAC, and the Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group, London, U.K.: Comparison of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barre syndrome. Presented at the American Neurological Association meeting, October, 1996, Miami.
6. Irani DM, Cornblath DR, Chaudhry V, Borel C, Hanley DF: Relapse in Guillain-Barre syndrome after treatment with human immune globulin. Neurology 1993;43:872-875.
7. Kennedy RH, Danielson MA, Mulder DW, Kurland LT: Guillain-Barre syndrome: a 42-year epidemiological and clinical study. Mayo Clin Proc 1978;53:93-99.
8. Kleyweg RP, van der Meche FGA: Treatment related fluctuations in Guillain-Barre syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 1991;54:957-960.
9. Loffel NB, Rossi LN, Mumenthaler M, Lutschg J, Ludin HP: The Landry-Guillain-Barre syndrome: complications, prognosis and natural history. J Neurol Sci 1977;33:71-79.
10. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group: Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatment in Guillain-Barre syndrome. Lancet 1997;349:225-230.
11. Pleasure DE, Lovelace RE, Duvoisin RC: The prognosis of acute polyradiculoneuritis. Neurology 1968;18:1143-1148.
12. Samantray SK, Johnson SC, Mathai KV, Pulimood BM: Landry-Guillain-Barre-Strohl Syndrome: a study of 302 cases. Med J Aust 1977;2:84-91.
13. Tanaka M: Different mechanisms may operate in therapies for AIDP and multifocal motor neuropathy [letter]. Muscle Nerve 1994;17:1232-1233.
14. Van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barre Study Group: A randomized trial comparing intrave- nous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992;326:1123-1129.
15. Wijdicks EFM, Ropper AH: Acute relapsing Guillain-Barre syndrome after long asymptomatic intervals. Arch Neurol 1990;47:82-84.
16. Winer JB, Hughes RAC, Osmond C: A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51:605-612.